What is Lu PSMA (Lutetium-Prostate Specific Membrane Antigen) Therapy?

Lu177 PSMA Therapy is a treatment for patients with prostate cancer, especially those who have become refractory to conventional therapy. Lutetium PSMA therapy helps to slow down the growth of the cancer cells, reduce the size of the tumours and most importantly improve the quality of life of the patients by reducing the pain caused by the cancer.

Many prostate cancers, in particular those that have spread or become resistant to hormonal therapies, express a unique receptor on their cell surface called Prostate Specific Membrane Antigen (PSMA). When Prostate Cancer metastasizes i.e. spreads to other parts of the body, the PSMA receptor is expressed over the sites of metastases as well.

How does Lu PSMA Therapy Work?

Lutetium-177 is a radioactive substance that emits beta radiation, a destructive kind of radiation. Lutetium-177 is bound to a small peptide which attaches to the PSMA receptor expressed on the cancer cell surface. The Lutetium 177 – PSMA complex, thus attached to the prostate cancer cell, then emits killing radiation causing cell death of the cancer cell. Since the penetration of the emitted beta particle is very small, the surrounding normal cells are spared.

How is the Therapy Done?

Lu177 PSMA is administered intravenously. The patient is admitted to the hospital for 24 hours. A kidney function scan called a MAG3/EC scan is done prior to the administration of the Lu177 PSMA.

What are the Side Effects of Lu PSMA Therapy?

Lu177 PSMA is well tolerated. The most common side effects are a slightly dry mouth, fatigue and nausea. There may also be a slight fall in the white blood cells and platelets about 2 – 3 weeks after the Lu177 PSMA administration.

What is the Response Rate With Lu PSMA Therapy?

The response rates of Lu177 PSMA depend on the tumour biology of prostate cancer, the initial Gleason Score, the extent of disease and the responses to prior therapies. Typically, more than 70% of patients demonstrate a reduction in S. PSA and a shrinkage of tumours following Lu177 PSMA therapy.

When would the doctor consider using this Therapy?

Lu PSMA Therapy is a very specific therapy and is used for managing metastatic Prostate Cancer or when Prostate Cancer is no longer responsive to other types of treatment.

What are the Treatment Schedules with Lu PSMA Therapy?

Most patients undergo three-four treatment cycles at intervals of 8-12 weeks. The number of cycles and the interim duration may vary between individuals depending on the response and interim assessments.

Why should I choose the nuclear medicine therapy center at Fortis Memorial & Research Institute (FMRI), Gurugram (Haryana, India)?

The Nuclear Medicine Therapy Centre at FMRI was one of the first institutes to offer Radio-ligand Therapy with Lu PSMA, and today, the center receives patients from the country and from across the world.

Privacy Policy | Nuclear Medicine Therapy in India

Tailored Privacy Policy for TPPL Second Read Service

Theranostic Physicians Private Limited ("TPPL" or "we") takes the privacy of your information seriously. This privacy notice ("Privacy Notice") describes the types of personal information we collect from you through our website nuclearmedicinetherapy.in, including the PET-CT Second Read service at /second-read (including sub-domains and microsites). It covers the purposes for collecting that information, parties with whom we may share it, security measures for your data, your rights and choices, and how to contact us about our privacy practices. Carefully read this Privacy Notice before using or availing our PET-CT Second Read service.

Definitions
In this Privacy Notice:

Cookies: A small file placed on your device by our website when you visit or use features. Cookies allow the site to remember actions or preferences for a period.

Data: Includes non-personal, personal, and sensitive personal information about you that could identify you directly or indirectly when using our site, including health data.

Data Protection Laws: Applicable laws relating to Data processing.

Service Providers: Entities to whom we disclose Data under contract for specific purposes.

TPPL: Theranostic Physicians Private Limited, incorporated in India, registered office at N-5, D Block, Saket, New Delhi 110017.

User or you: The natural person accessing our website.

What Data We Collect

TPPL collects Data for the PET-CT Second Read service, including:

Contact information: Name, email, phone, city/country, treating doctor details.
Health-related information: PET-CT images, prior reports, clinical history, diagnosis, treatment details (sensitive personal data).
Transaction information: Payment details, transaction history for the service fee.
Technical information: IP address, device/browser usage, collected via cookies/pixels.
Your feedback or reviews on the service.

How We Collect Data

Information You Give Us: Entered via the Second Read form (e.g., uploads, clinical details, registration).
Automatic Collection: IP address, device details, usage via cookies for site performance/security.
From Other Sources: Third-party authorizations or previously shared data, if consented.
You can decline Data provision or adjust cookie settings, though this may limit service access.

Our Use of Data
We use Data to:

Fulfill the Second Read service: Receive uploads, enable specialist review, deliver reports.
Communicate: Confirmations, queries, report delivery, support.
Improve/secure service: Quality assurance, audits, fraud prevention.
Legal compliance: Record-keeping, regulatory/tax obligations.
Processing occurs with consent, for contract performance, legal needs, or legitimate interests. Sensitive health data requires explicit consent.

Minors

The service targets adults; minors under 18 require parent/guardian involvement and consent.

Sharing of Data
Data shared with:

Internal team: TPPL nuclear medicine specialists for review/reporting.
Service Providers: Hosting, imaging platforms, payments, analytics (contract-bound, secure).
Authorized parties: Hospitals/doctors if you request report sharing.
Legal: Authorities for compliance, fraud protection, rights/safety. No selling of Data. Providers must secure Data per our instructions.

Keeping Data Secure

Technical/organizational measures protect Data on secure India-based servers. Report suspected breaches to us immediately.

Retention of Data

Retained as needed for service, medical records (legal minimum), disputes; then deleted/anonymized. Backups for audit/legal purposes.

Your Rights and Choices

Rights: Access, correct, withdraw consent, delete (where lawful). Updates ensure accuracy. Exercise via contact below; withdrawal may impact service/report retention. Data hosted in India; processed per this Notice/law.

App Permissions

Not applicable (web-based service).

Changes to This Privacy Notice

Updates posted on site; continued use implies acceptance. Check frequently.

How to Contact Us

Email requests to access/update/withdraw: info@nuclearmedicinetherapy.in. Response within 30 days.

Grievance Officer
Name: Dr. Dharmender Malik, Director TPPL
Email: dr.dharmendermalik@nuclearmedicinetherapy.in
Tel: 9468 444 004
Address: N-5, D Block, Saket, New Delhi 110017.

Privacy Policy